No. 2 – Gilead – 4.1%
As Amgen showed us, attractive yields can occasionally be found in the biotech sector. Though remdesivir did not turn out to be the Covid-19 treatment of choice, California-based GILD has enjoyed recent successes from its HIV and Hepatitis drugs.